Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.


Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 17 04 2019
accepted: 10 08 2019
pubmed: 25 8 2019
medline: 29 10 2019
entrez: 25 8 2019
Statut: ppublish

Résumé

Immunotherapy is effective in head and neck squamous cell carcinoma (HNSCC), but only a minority of patients responds to immune checkpoint blockade (ICB). To contribute to a better understanding of the underlying immune biology, we combined histomorphological evaluation and molecular analysis of the HNSCC immune microenvironment in the TCGA cohort. Analyzing digital HE-stained slides, a method for classification of tumor infiltrating lymphocytes (TILs) in the intra-epithelial compartment (ieTILs, present vs. absent) and the stromal compartment (strTILs, high vs. low) was established. We also analyzed the abundance of eight immune cell populations (estimated from RNAseq data) and PD-L1 mRNA expression. Status of ieTILs and status of strTILs were concordant for 61%, but discordant for 39% of tumors. In univariate survival analysis, ieTILs were a positive prognostic marker for DFS in the study cohort (HR = 0.66, p = 0.015) and in the HPV- subcohort (HR = 0.68, p = 0.04), but not in the HPV + subcohort. T cells were a positive prognostic marker for DFS in the study cohort (HR = 0.80, p = 0.03) and in the HPV + subcohort (HR = 0.20, p = 0.001), but not in the HPV- subcohort. In univariate survival analysis, PD-L1 mRNA expression was neither associated with DFS nor with OS. However, in bivariate and multivariate analyses including both PD-L1 mRNA levels and T cells, PD-L1 was a negative prognostic marker of DFS and OS, while T cells remained a positive prognostic marker. In conclusion, ieTILs and strTILs were non-redundant biomarkers in HNSCC and should be evaluated separately. The identified prognostic markers should be evaluated for predictivity in ICB-treated patients.

Identifiants

pubmed: 31444607
doi: 10.1007/s00262-019-02378-w
pii: 10.1007/s00262-019-02378-w
doi:

Substances chimiques

B7-H1 Antigen 0
Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1443-1454

Subventions

Organisme : German Cancer Consortium (DKTK)
ID : None
Organisme : German Cancer Consortium (DKTK)
ID : None
Organisme : German Cancer Consortium (DKTK)
ID : None
Organisme : German Cancer Consortium (DKTK)
ID : None
Organisme : German Cancer Consortium (DKTK)
ID : None

Auteurs

Mohamed Badr (M)

Institute of Pathology, Charité Hospital, Berlin, Germany.

Korinna Jöhrens (K)

Institute of Pathology, Charité Hospital, Berlin, Germany.
Institute of Pathology, University Hospital Dresden, Dresden, Germany.

Michael Allgäuer (M)

Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.

Melanie Boxberg (M)

Institute of Pathology, Technical University of Munich, Munich, Germany.

Wilko Weichert (W)

Institute of Pathology, Technical University of Munich, Munich, Germany.
German Cancer Consortium (DKTK), Berlin, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Consortium (DKTK), Munich, Germany.

Ingeborg Tinhofer (I)

Department of Radiooncology and Radiotherapy, Charité Hospital, Berlin, Germany.

Carsten Denkert (C)

Institute of Pathology, Charité Hospital, Berlin, Germany.
Institute of Pathology, University Hospital Marburg (UKGM) and Philipps-University Marburg, Marburg, Germany.
German Cancer Consortium (DKTK), Berlin, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Consortium (DKTK), Munich, Germany.

Peter Schirmacher (P)

Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
German Cancer Consortium (DKTK), Berlin, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Consortium (DKTK), Munich, Germany.

Albrecht Stenzinger (A)

Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
German Cancer Consortium (DKTK), Berlin, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Consortium (DKTK), Munich, Germany.

Jan Budczies (J)

Institute of Pathology, Charité Hospital, Berlin, Germany. jan.budczies@med.uni-heidelberg.de.
Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany. jan.budczies@med.uni-heidelberg.de.
German Cancer Consortium (DKTK), Berlin, Germany. jan.budczies@med.uni-heidelberg.de.
German Cancer Consortium (DKTK), Heidelberg, Germany. jan.budczies@med.uni-heidelberg.de.
German Cancer Consortium (DKTK), Munich, Germany. jan.budczies@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH